Adaptimmune downgrades trial design after FDA clinical hold
Oxford-based immuno-oncology play Adaptimmune has been obliged by the FDA to alter the trial design of a Phase I/II study in patients with MRCLS. A partial clinical hold was lifted now.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Multiple sclerosis diagnosis in early stage
Belgian and German researchers have presented a new imaging tool that can track immune cells invading the brain in the initial stages of multiple sclerosis (MS).
BIO Europe with new record numbers
Despite declining numbers of IPOs, financing rounds and licensing deals, the European biotech sector presented itself optimistic and self-confident during BIO-Europe in Cologne. The three-days partnering event again see a record number of participants.
AZ withdraws lung cancer drug from EU lead market
After AstraZeneca removed its NSCLC drug osimertinib from the German market following a benefit assessment of German health technology assessor G-BA negatively impacting price negotiations, the German oncologist association DGHO accuses the G-BA not to act in the best interest of lung cancer patients.
Bioregions deliver action plan blueprint
While DG Research has delayed its update on the European Bioeconomy Strategy and Action Plan until next June, the Central and Eastern Bioregions presented a blueprint that proposes key actions aimed at integrating the goals of the European Commissions circular economy and the bioeconomy strategies.
Germany lagging behind in stem cell research
A new analysis comparing the amount of funding invested into stem cell research clearly demonstrates declining investment in Germany. In contrast, the US, the UK, Sweden and Japan have increased their investments into the future field.
Merck drops MS collaboration with Apitope
Apitope said it has regained global rights to its IL-10-bolstering vaccination ATX-MS-1467 for remitting-relapsing multiple sclerosis from Merck KGaA. A 2009 contract forsaw that Merck will take over commercialisation cost following Phase II testing. Phase II data are due to be published in Q4/2016.
EPO rules threaten biotech industry
The European Patent Offices decision to speed up examination of patent applications to 12 months without any transition period is set to ruin biotech SMEs financially and may send a blocking signal to innovators.
Roches NSLC mAb outperforms chemo
Roche is making up lost ground in immuno-oncology. The Swiss companys PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy.
Synvina: BASF and Avantium join forces
The new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics.